Arndt Weinmann

Suggest Changes
Learn More
To prospectively compare SIRT and DEB-TACE for treating hepatocellular carcinoma (HCC). From 04/2010–07/2012, 24 patients with histologically proven unresectable N0, M0 HCCs were randomized 1:1 to(More)